Encoded Therapeutics’ Dravet syndrome gene regulation program ETX101 is reporting updated clinical data showing dose-dependent seizure reduction through 52 weeks in a Phase I/II setting, according to an ASGCT Presidential Symposium update. The report describes a one-time AAV9-based approach designed to increase SCN1A expression by restoring physiologic sodium channel function in inhibitory interneurons. The dataset was described as expanding patient enrollment, adding longer-term follow-up, and including additional observations at the highest dose level. Early top-dose results were discussed alongside concomitant immune-suppression considerations, with the intent to understand how immunomodulation affects both expression and clinical outcomes. In a closely related line of reporting, separate analysis highlighted concerns that immune-suppressive regimens used to reduce gene therapy viral immune responses could potentially blunt effectiveness—an issue central to gene therapy risk-benefit management. Taken together, the items underscore that in CNS gene therapy, immune suppression and durability of gene expression remain tightly coupled clinical variables requiring careful protocol refinement.